Matthew Reed
PhD, DABT, Fellow ATS

Dr. Reed is a pharmacologist, board certified toxicologist, past ABT Board Member, and Fellow of the Academy of Toxicology Sciences (ATS). He has been a part of multiple successful R&D
programs that that have transitioned to IND, NDA and other regulatory registration milestones for small molecules, biologics, oligonucleotides, and alternative fuel additives. Dr. Reed has
developed large scale hazard assessment programs, Integrated Drug Development Plans and timelines, and has developed hundreds of safety and pharmacology programs for R&D
initiatives.

Specifically he has overseen and consulted on initiatives to include toxicant/ drug delivery, applied toxicology studies, formulation/device feasibility and development, pharmacokinetics, pharmacology, safety pharmacology, pivotal IND and NDA GLP
compliant studies, etc. Dr. Reed has been an awardee, PI/ Co-PI, or subcontract PI of over $51M in federal R&D grants and contracts for drugs and vaccines (delivery by multiple routes)
working with government funded commercial firms, NIH, BARDA and DOD to develop pharmaceutics for clinical indications as well as combat, homeland, and defense security threats.